Clinical Evidence
The HelioLiver LDT delivers superior performance characteristics when compared to traditional testing for HCC
First Look at HelioLiver Data
New results recently unveiled from the state-of-the-art CLiMB Trial: “A prospective, blinded, multicenter U.S. evaluation of a multi-analyte blood-based test for the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis.”
HELIOLIVER
ULTRASOUND
29%
0%
TUMOR SIZE: ≤ 2 CM
Potential treament options:
Resection or transplant
Listen to Helio’s data presentation at the 2024 European Association for the Study of the Liver (EASL) Congress
Presenter: Dr. Richard Van Etten, Helio Genomics’ Chief Medical Advisor
Length: 13:09 minutes
Our Scientific Advisors
Richard Van Etten, MD, PhD
Chief Medical Advisor
Wei Li,PhD
Chief Bioinformatics Advisor
Mindie Nguyen, MD, MAS, AGAF, FAASLD
Hepatology Advisor and Lead Principal Investigator in CLiMB
Robert Gish, MD
The Hepatitis B Foundation
Want to learn more?
Our team is happy to hear from you and answer any questions you may have